Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hitanercept (T0001) in Rheumatoid Arthritis
NCT02481180Phase 1Terminated
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Nov 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Hitanercept in rheumatoid arthritis (RA) (5 arms), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerance Dose at 4 weeks, Peak Plasma Concentration at 14 weeks and 2 more. Started Jul 2015; status: terminated.
02
Drugs
Hitanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02481180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481180.